While DNA is our business…
it’s patients who fill our hearts
Natera’s diverse teams blend a passion for patients with deep clinical, scientific, and technological roots.
Chief Executive Officer
Steve Chapman is Natera’s Chief Executive Officer and serves on the company’s board of directors. Mr. Chapman joined Natera in 2010 as Vice President of Sales, later becoming Chief Commercial Officer and then Chief Operating Officer. As COO, he led the company’s commercial entry into the highly competitive non-invasive prenatal testing market, in which the company’s Panorama® test became the market leader despite being fourth to market. Mr. Chapman was appointed CEO in January 2019 and has been instrumental in extending Natera’s core technology to address new organ health and oncology markets, achieving rapid commercial growth for the Prospera™ transplant assessment test and establishing Natera’s leadership in molecular residual disease testing with Signatera.™ Since becoming CEO, Natera has achieved year-on-year revenue growth of over 40% and has consistently outperformed earnings expectations. Prior to joining Natera, Mr. Chapman worked at Genzyme Genetics, where he was credited with delivering record-breaking commercial growth and strategies that changed pregnancy genetic testing. Mr. Chapman began his career as a researcher in the department of human genetics at UCLA designing arrays identifying SNPs associated with multiple sclerosis. He graduated with honors and holds a B.S. in Microbiology, Immunology, and Molecular Genetics from UCLA.
Chief Operating Officer
Robert Schueren is an accomplished industry veteran with extensive molecular diagnostics, genomics, and pharma experience. Mr. Schueren has enjoyed an expansive 30-year career and has been a driving force behind rapid business growth at both start-up and large biotech companies. Most recently, he was CEO of IntegenX Inc., playing a critical role in the growth and success of the company, and ultimate acquisition by Thermo Fisher Scientific, as well as successfully leading a lobbying effort to pass the Rapid DNA Act of 2017. Mr. Schueren previously held executive leadership roles including GM of Genomics at Agilent Technologies, Global Head of Clinical Biomarkers and Operations, and Deputy Global Head of Molecular Medicine Labs for Genentech, Inc. He formerly held leadership and commercial roles at Arcturus Bioscience, Accumetrics, Biosite Diagnostics, Gen-Probe, and Abbott Labs. Mr. Schueren received a BS in Pharmacy from Temple University.
Mike Brophy, MBA
Chief Financial Officer
Mike Brophy is Natera’s CFO, he joined Natera in 2015 serving as Natera’s Senior Vice President of Finance and Investor Relations, and prior to that as Vice President of Corporate Development and Investor Relations. Prior to joining Natera, he served as an executive director and as a vice president in the investment banking division of Morgan Stanley, where he focused on advising corporate clients in the life science tools and diagnostics sector. Mr. Brophy holds a master’s degree in business administration from the University of California, Los Angeles, and a Bachelor of Science degree in economics from the United States Air Force Academy. His military career included leading a multi-agency, 10-person team on a $1.4 billion contract to modernize 10 remote satellite tracking stations worldwide.
Olesya Anisimova, CPA
Chief Accounting Officer
Eric Evans, PhD
Chief Scientific Officer
Dr. Eric Evans joined Natera in 2020 as Chief Scientific Officer. Prior to joining Natera, he was co-founder and Chief Scientific Officer of Counsyl for 12 years. In that role, he led R&D and clinical operations for a molecular diagnostics portfolio in women’s health and oncology. He has authored papers in reproductive genetics and molecular diagnostics, including journals such as JAMA, Genetics in Medicine, Clinical Chemistry, and Prenatal Diagnosis. He received his B.S. in Biological Sciences from the University of Delaware and his Ph.D. in Genetics from Stanford University. While at Stanford, he was a Stanford Graduate Fellow working on the genetics of aging and the immune system.
Ramesh Hariharan, PhD, MBA
General Manager, Women's Health
Chief Technology Officer
Rishi Kacker serves as Natera’s Chief Technology Officer, bringing 20-years of experience in software, genetics, and health tech entrepreneurship. At Natera he is responsible for leading a team including product, UX, software engineering and IT with the mission to expand access to genetic testing for millions each year through innovations/transformation in the patient and provider experience. Additionally, the team has launched a massive clinico-genomic data and research platform being used to accelerate our knowledge of genetic disease. Prior to Natera, Mr. Kacker was the Chief Technology Officer at Myriad Genetics and co-founder and SVP of Technology at Counsyl (acquired by Myriad Genetics). He started his career as co-founder of Voltage Security, a data security and enterprise software business that was acquired by HP Enterprise. Mr. Kacker holds a B.S. degree in computer science from Stanford University.
J. Dianne Keen-Kim, PhD, FACMG, HCLD (ABB)
CLIA Laboratory Director
As Senior Vice President of Laboratory Affairs & Quality, and Natera’s corporate CLIA Laboratory Director, Dr. Keen-Kim is responsible for the overall operation and administration of the clinical laboratories, as well as Natera’s Quality culture. Since joining Natera in 2018, Dr. Keen-Kim built the genetic variant classification and curation processes, has grown data analysis and clinical reporting operations 4-fold, and provides daily quality oversight and risk management in oncology, women’s health, and transplant diagnostics. With expertise in cell-free DNA, Next Generation Sequencing, and automation technologies, Dr. Keen-Kim earned a bachelor’s degree from Carnegie Mellon University, a Ph.D. from MIT, completed her fellowship at UCLA, and currently serves as an Adjunct Clinical Professor at Stanford University School of Medicine. She is licensed by California and New York to direct medical laboratories and maintains three HHS-approved board certifications. Dr. Keen-Kim is a mentor and champion for women leaders and is passionate about staff training and development to create growth opportunities for the next generation.
Solomon Moshkevich, MBA
General Manager, Oncology
Anu Pai, MS
Head of R&D Program Management
Anu Pai leads Natera’s R&D Program Office. With more than 25 years of experience in product development and management, Anu joined Natera from Roche Diagnostics where she held various leadership roles in assay development, product and portfolio management, developing and launching PCR-based products for infectious diseases & blood screening, microbiology and cervical Cancer screening. Anu started her career as an R&D scientist working on multiplex PCR Assay for screening HIV, HCV and HBV, she has also managed large scale clinical trials, as well as design control and regulatory processes, having worked on IVD, RUO, IUO and Companion Diagnostics products. Anu holds an M.S in Chemistry from the University of Kentucky.
Sheetal Parmar, MS, CGC
Head of Clinical Services
Daniel Rabinowitz, LLM
Secretary & Chief Legal Officer
Daniel Rabinowitz is Secretary and Chief Legal Officer of Natera. Prior to joining Natera, he was a corporate partner at the law firm McDermott, Will & Emery, and, before that, was also a corporate lawyer at the law firm Davis Polk & Wardwell. He has worked in the United States and Europe advising domestic, foreign, public, and private companies on capital raisings, M&A, investment management and compliance with US federal and state securities law. He has studied genetics, biochemistry, and molecular biology at Harvard University Extension School and attended courses on the legal and ethical aspects of biotechnology at Harvard Law School. Mr. Rabinowitz completed his B.A. and LL.B. degrees at the University of the Witwatersrand, South Africa, graduating at the top of his law school class, and completed his LL.M. at New York University School of Law with both Rotary Foundation and Fulbright Scholarships. Admitted in New York only.
Matthew Rabinowitz, PhD
Dr. Matthew Rabinowitz is co-founder of Natera and currently serves as the Executive Chairman of the board of directors. He served as Natera’s Chief Executive Officer from 2005 to 2018. Prior to co-founding Natera, Dr. Rabinowitz founded Rosum Corporation, a location-systems company that used terrestrial digital television broadcasts to enhance GPS indoors, where he was Chief Executive Officer from 2000 to 2003 and Chief Technology Officer from 2003 to 2006. For this technology, Dr. Rabinowitz received the Scott Helt Memorial Award from the IEEE. From 1998 to 2000, he served as co-founder and Chief Scientist of Panop.com Inc., a technology company for personalized online merchandising that was sold after roughly two years for $100M. Dr. Rabinowitz served as a consulting professor at Stanford University for 8 years and in 2018, began as Visiting Faculty in the Genetics Department of Harvard University. He has served as Principal Investigator on six research grants from the National Institutes of Health and has authored over 100 patents and academic papers, including journals such as IEEE Transactions, Bioinformatics, Science, Nature, JAMA Oncology, Journal of Clinical Oncology, Human Reproduction, Molecular Human Reproduction, Fertility and Sterility, Obstetrics and Gynecology, Ultrasound in Obstetrics and Gynecology, and Genome Medicine. Two companies that he founded received the World Economic Forum Technology Pioneer Award, awarded each year to 20 companies worldwide. He is on the board of the foundation of the American College of Medical Genetics and is a board member, advisor, and angel investor for multiple companies in biotechnology, diagnostics, gene editing, machine learning, communications, and cleantech. Dr. Rabinowitz completed one year at the University of the Witwatersrand, South Africa, and holds a Bachelor of Science degree in Physics, a Master of Science in Electrical Engineering, and a Ph.D. in Electrical Engineering with a minor in Aeronautics and Astronautics, all from Stanford University.
Bernie Tobin, MBA
General Manager, Organ Health
Bernie Tobin is responsible for strategy and execution for Natera’s organ health products. Mr. Tobin is a 25-year veteran of the healthcare industry with his most recent role serving as President of Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics. Crescendo focused on using proteomics to deliver precision medicine to patients with autoimmune disorders.
Previously, Mr. Tobin held several senior-level positions at Amgen including General Manager of both the Netherlands and Brazil and Global Head of Commercial Excellence. In addition, he led the global integration of a business development acquisition in over 100 countries. Prior to that, Mr. Tobin held a variety of leadership roles in the commercial organization at Eli Lilly and Co. He received his B.S. degree in Public Service and Administration from Iowa State University and his M.B.A. from the Fuqua School of Business, Duke University.